KLTO

Klotho Neurosciences, Inc. develops essential medicines for the treatment of chronic diseases such as cancer, cardiovascular, and neurodegenerative disorders. The Company's licensed platforms, namely, a generic drug portfolio and a biosimilar biologics platform uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Its primary focus is the advancement of a sustainable portfolio of cell and gene therapy product candidates for age-associated neurologic diseases, both rare orphan diseases and diseases in larger patient populations. The Company's two lead gene therapy product candidates are KLTO-101 (AAV9-CMV-sKL) for the treatment or prevention of Alzheimer’s disease, and KLTO-202 (AAVmyo-Des-sKL) gene therapy product for the treatment and prevention of Lou Gehrig’s disease (amyotrophic lateral sclerosis).

Wall Street analysts forecast KLTO stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for KLTO is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Klotho Neurosciences Inc revenue for the last quarter amounts to -1.85M USD, decreased -35.45 % YoY.

Klotho Neurosciences Inc. EPS for the last quarter amounts to USD, decreased -100.00 % YoY.

Klotho Neurosciences Inc (KLTO) has 3 emplpoyees as of December 15 2025.

Today KLTO has the market capitalization of 29.04M USD.